Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Is Amgen a Buy?

There's good news and there's bad news for this big biotech.

Is Auxly Cannabis a Buy?

This marijuana stock has a lot of potential. But that potential has yet to be realized.